Skip to main content
SpringerLink
Log in

Systemically Administered Drugs

  • Chapter
Book cover Drug Delivery Systems in Cancer Therapy

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 382 Accesses

Abstract

Although the use of drugs in the management of cancer has made a significant impact on the outcome of most types of malignancies, one of the lingering challenges in cancer therapeutics is how to influence the outcome of cancer treatment by optimal and careful application of anticancer drugs. Addressing this challenge requires the adoption of treatment strategies that employ sound pharmacologic principles in the use of anticancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37:596–599.

    Article  PubMed  CAS  Google Scholar 

  2. Gagliano RG, Costanzi II. Paraplegia following intrathecal methotrexate. Report of a case and review of the literature. Cancer 1976; 37:1663–1668.

    Article  PubMed  CAS  Google Scholar 

  3. Siegal T, Melamed E, Sandbank U, Cantane R. Early and delayed neurotoxicity or mitoxantrone and doxorubicin following subarachnoid injection. J Neurooncol 1988; 6:135–140.

    Article  PubMed  CAS  Google Scholar 

  4. Didolkar MS, Jackson AJ, Lesko LJ, et al. Fharmacokinetics or dacarDazine in tne regional perusion of extremities with melanoma. J Surg Oncol 1996; 63:148–158.

    Article  PubMed  CAS  Google Scholar 

  5. Carlson RW. Continuous intravenous infusion chemotherapy, in The Chemotherapy Source Book (Perry MC, ed). Williams & Wilkins, Baltimore, MD, 1996, pp 225–251.

    Google Scholar 

  6. Derendorf H, Hochhaus G, Meibohm E, Mollmann H, Earth J. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101(4 Pt. 2):8440–8446.

    Article  Google Scholar 

  7. Suri A, Estes KS, Geisslinger G, Derendorf H. Pharmacokinetic-pharmacocynamic reiationsmps ror analgesics. Int J Clin Pharmacol Ther 1997; 35(8):307–323.

    PubMed  CAS  Google Scholar 

  8. Muller M, Rohde B, Kovar A, Georgopoulos A, Eichler HG, Derendort H. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J Clin Pharmacol 1997; 37(12):1108–1113.

    PubMed  CAS  Google Scholar 

  9. Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AB. Ettect ot U6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51:3367–3372.

    PubMed  CAS  Google Scholar 

  10. Kumanohoso T, Natsugoe S, Shimada M, Aikou T. Enhancement ot therapeutic efficacy or bleomycin Dy incorporation into biodegradable poly-d,I-lactic acid. Cancer Chemother Pharmacol 1997; 40:112–116.

    Article  PubMed  CAS  Google Scholar 

  11. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H. Optimizing interstitial delivery of BUN U from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 1997; 39:383–389.

    Article  PubMed  CAS  Google Scholar 

  12. Sharma D, Chelvi TP, Kaur J, et al. Novel Taxol formulation: polyvinylpyrrolidone nanoparticieencapsulated Taxol for drug delivery in cancer therapy. Oncology Res 1996; 8(8–9):281–286.

    CAS  Google Scholar 

  13. Chonn A, Cullis PR. Recent advances in liposomal drug-delivery systems. Curr. opinion in Biotecnnotogy 1995; 6(6):698–708.

    Article  CAS  Google Scholar 

  14. Schiller JH, Storer B, Berlin J, et al. Amifostine, Cisplatin, and Vinblastme in metastatic non-smallcell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14:1913–1921.

    PubMed  CAS  Google Scholar 

  15. Kemp G, Rose P, Lurain I, et al. Amifostine pretreatment for protection against cyclopnospnamideinduced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14:2101–2112.

    PubMed  CAS  Google Scholar 

  16. Presant CA, Scolaro M, Kennedy P, et al. Liposomal daunorubicin treatment of mv-associated Kaposi’s sarcoma. Lancet 1993; 341:1242–1243.

    Article  PubMed  CAS  Google Scholar 

  17. Slepushkin VA, Simoes S, Dazin P, et al. Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivo. J Biological Chem 1997; 272(4):2382–2388.

    Article  CAS  Google Scholar 

  18. Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47:1–19.

    Article  PubMed  CAS  Google Scholar 

  19. Yeh K-H, Shun C-T, Chen C-L, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998; 82:1626–31.

    Article  PubMed  CAS  Google Scholar 

  20. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56:783–788.

    PubMed  CAS  Google Scholar 

  21. Bajetta E, Camaghi C, Somma L, Stampino CG. A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 1996: 82:450–452.

    PubMed  CAS  Google Scholar 

  22. Dolan ME, Pegg AB. 06-benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3:837–847.

    PubMed  CAS  Google Scholar 

  23. Goldie JH, Coldman AJ. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 1984; 44:3643–3653.

    PubMed  CAS  Google Scholar 

  24. Frei E III, Canellos G. Dose: a critical factor in cancer chemotherapy. Am J Med 1980; 69:585–594.

    Article  PubMed  Google Scholar 

  25. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology 1998: 12(4):537–547.

    PubMed  CAS  Google Scholar 

  26. Foth H. Role of the lung in accumulation and metabolism of xenobiotic compounds-implication for chemically induced toxicity. Crit Rev Toxicol 1995; 25(2):165–205.

    Article  PubMed  CAS  Google Scholar 

  27. Bakhle YS. Pharmacokinetic and metabolic properties of lung. Br J Anaesth 1990; 65:79–93.

    Article  PubMed  CAS  Google Scholar 

  28. Millay RH, Klein ML, Shults WT, Dahlborg SA, Neuwelt EA. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am J Ophthalmol 1986; 102:626–632.

    PubMed  CAS  Google Scholar 

  29. Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 1984; 15:362–366.

    Article  PubMed  CAS  Google Scholar 

  30. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 1994; 81:752–758.

    Article  PubMed  CAS  Google Scholar 

  31. DeMario MD, Ratain MI. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998; 16(7):2557–2567.

    PubMed  CAS  Google Scholar 

  32. Shapiro WR, Green SB, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992; 76:772–781.

    Article  PubMed  CAS  Google Scholar 

  33. Wu MB, Liebowitz DN, Mikolajezak, KE, Lin AM, Dolan ME. Sensitivity of mutant 06-alkylguanineDNA alkyltransferases (AGT) to 06-Benzylguanine (BG) and 06-Benzyl-8-oxoguanine (8-oxoBG). Proc Am Assoc Ca Res 1998; 39:517.

    Google Scholar 

Download references

Authors
  1. Reginald B. Ewesuedo MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark J. Ratain MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ChemGenex Therapeutics, Inc., Menlo Park, CA, USA

    Dennis M. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ewesuedo, R.B., Ratain, M.J. (2004). Systemically Administered Drugs. In: Brown, D.M. (eds) Drug Delivery Systems in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-427-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-427-6_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-238-4

  • Online ISBN: 978-1-59259-427-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation